“Amid the tragedy and confusion surrounding the COVID-19 pandemic, there has been consensus on at least one point: We need testing for the disease, and lots of it — yesterday.
Widespread testing will allow for better-informed public health decision-making, make quarantining more efficient and greatly assist companies and employees in getting back to work.
The market has begun to respond, with dozens of companies announcing plans to import, distribute and administer antibody-based serological tests using blood samples and with labs gearing up to conduct more precise polymerase chain reaction tests using nasal swabs. Currently, these two testing types are the leading ways to test individuals for COVID-19. Much of the cost of that testing will be billed to private health insurers.”
To read full article, click here. *subscription required